UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 25, 2008
MEDAREX, INC.
(Exact name of registrant as specified in its charter)
|
New Jersey |
|
0-19312 |
|
22-2822175 |
|
(State or other jurisdiction |
|
(Commission |
|
(IRS Employer |
|
of incorporation) |
|
File Number) |
|
Identification No.) |
|
707 State Road, Princeton, N.J. |
|
08540-1437 |
|
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code: (609) 430-2880
|
N/A |
|
(Former name or former address, if changed since last report.) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On April 25, 2008, Medarex, Inc. and Bristol-Myers Squibb Company issued a press release to announce a delay in the Biologics License Application submission for ipilimumab, an investigational immunotherapy for patients with advanced metastatic melanoma.
A copy of the press release is furnished as Exhibit 99.1 to this Current Report.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits. The following press release is furnished as an exhibit to this Current Report:
|
Exhibit Number |
|
Description |
|
|
|
|
|
99.1 |
|
Press release issued April 25, 2008. |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
MEDAREX, INC. |
|
|
|
|
Date: April 25, 2008 |
/s/ Christian S. Schade |
|
|
Christian S. Schade, |
|
|
Senior Vice President and Chief Financial Officer |
3
EXHIBIT INDEX
|
Exhibit Number |
|
Description |
|
|
|
|
|
99.1 |
|
Press release issued April 25, 2008. |
4